Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreat...Подробнее

Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLLПодробнее

Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLLПодробнее

The future of fixed-duration therapy in CLLПодробнее

Fixed-duration treatment strategies for frontline and relapsed CLLПодробнее

Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclaxПодробнее

CLL14: feasibility of fixed-duration frontline therapy in CLLПодробнее

CAPTIVATE: fixed-duration ibrutinib plus venetoclax in patients with CLL/SLLПодробнее

Venetoclax and Obinutuzumab in CLLПодробнее

CLL: Venetoclax in combination with obinutuzumabПодробнее

Factors to consider when selecting between continuous and fixed-duration therapy in CLLПодробнее

CLL14: Venetoclax plus obinutuzumab for CLLПодробнее

Fixed-duration ibrutinib and venetoclax for first-line CLLПодробнее

GLOW: Assessing ibrutinib plus venetoclax in CLLПодробнее

CLL14: Venetoclax plus obinutuzumab in untreated CLLПодробнее

Dr. Abedin on the Role of Venetoclax Plus Obinutuzumab in CLLПодробнее

What Is the Best Strategy for Frontline Venetoclax Plus Obinutuzumab in CLL?Подробнее

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses CIT in frontline CLLПодробнее

An update on Celestial-TNCLL: fixed-duration sonrotoclax plus zanubrutinib in CLLПодробнее